There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type | HazMat fee for 500 gram (Estimated) |
Excepted Quantity | USD 0.00 |
Limited Quantity | USD 15-60 |
Inaccessible (Haz class 6.1), Domestic | USD 80+ |
Inaccessible (Haz class 6.1), International | USD 150+ |
Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |
Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 15663-27-1 | MDL No. : | MFCD00011623 |
Formula : | Cl2H6N2Pt | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | DQLATGHUWYMOKM-UHFFFAOYSA-L |
M.W : | 300.05 | Pubchem ID : | 2767 |
Synonyms : |
cis-Platinum;CDDP;CACP;cis-Diamminedichloroplatinum;DDP;cis DDP;cis-diamminedichloroplatinum II;NSC 119875;cis-Diaminodichloroplatinum
|
Signal Word: | Danger | Class: | 6.1 |
Precautionary Statements: | P501-P263-P260-P270-P202-P201-P264-P280-P337+P313-P305+P351+P338-P308+P311-P332+P313-P301+P310+P330-P405 | UN#: | 3288 |
Hazard Statements: | H300-H316-H319-H360-H362-H370-H372-H340-H350 | Packing Group: | Ⅱ |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In 1,2-dimethoxyethane; at 100℃; for 7h; | I. Preparation of Et4N[PtCl3(NH3)] tetraethylammounium amminetrichloroplatinate; K[PtCl3(NH3)] potassium amminetrichloroplatinate A mixture of cisplatin (8.1 g) and <strong>[56-34-8]tetraethylammonium chloride</strong> (5.64 g) in 300 mL of N,N-dimethylacetamide was heated at 100 C. with bubbling of argon for 7 hours. The resulting dark orange solution was concentrated to a final volume of approximately 50 mL. To this mixture was added a solution of hexane and ethyl acetate (400 mL; 1:1 v/v). The resulting suspension was put in refrigerator (-5 C.) for 14 hours. The light pale yellow solution was then decanted and the orange oil was extracted with 100 mL of deionized water. The yellow precipitate was filtered, and the filtrate was lyophilized to give a yellow solid of pure tetraethylammounium amminetrichloroplatinate. The above platinate was dissolved in 100 mL of deionized water, and acid exchange resin was added. The mixture was stirred for 30 min. and the resin was filtered. The filtrate was concentrated to 10 mL, and 10 mL of saturated KCl solution was added. The resultant solution was put in a refrigerator at 2 C. for 16 hours to give the desired product of potassium amminetrichloroplatinate (orange solid, 2.62 g; 41%). 195Pt NMR delta-1880 ppm. Predicted HRMS for K2PtNH3Cl3: 394.824736; found: 394.824202. | |
This coordination complex was synthesized using a previously reported procedure (Giandomenico et al., Inorg. Chem. 34:1015-21 (1995)). A solution of cisplatin (2.34 g) and tetraethylamrmonium chloride (1.66 g) in fresh dimethylacetamide (200 mL) was heated to 100 C with stirring while purging with argon. The temperature was maintained for 7 h, and the solution volume was allowed to reduce to approximately 50 mL by the end of the reaction time. Care was made to prevent prolonged heating above 100 C. to avoid decomposition of the platinum reagent. After completion of the reaction, the reaction solution was allowed to cool to room temperature, 450 mL of a 1:1 hexane:ethyl acetate mixture was added, and the resultant solution cooled at -20 C overnight. This cooling precipitates out an orange product oil, which was easily separated from the supernatant solution. The orange product contains the tetraethylammonium salt of the desired platinum complex, (Et4N)[Pt(NH3)Cl3]. This oil was dissolved in 20 mL of water, and the solution allowed to sit for 30 min to allow for precipitation of unreacted cisplatin. This solution was filtered, and mixed with 50 mL of rinsed acidic Dowex 50W-X8 to affect ion exchange. The solution was again filtered to remove the resin, and the volume of the resultant solution was reduced to 1-2 mL by rotary evaporation. Crystals of K[Pt(NH3)Cl3] were isolated through the addition of a 3 mL of a saturated KCl solution to the ion exchanged [Pt(NH3)Cl3] solution. The resultant mixture was chilled at 5 C for several hours, and afforded orange crystalline K[Pt(NH3)Cl3]. Yield: 2.01 g (69%), 195Pt NMR(H2O): -1743 ppm [Pt(NH3)Cl3]+, FTIR (cm-1, KBr pellet): 3529, 3475, 1626, 1545, 1324, 544, 520. | ||
In N,N-dimethyl acetamide; at 100℃; for 6h;Inert atmosphere; | All four Pt intermediates were prepared using literature methods [27], with some modifications. To cisplatin (0.468 g,1.56 mmol) and <strong>[56-34-8]tetraethylammonium chloride</strong> (Et4NCl, 0.332 g,1.88 mmol) was added 40 mL of fresh reagent grade DMA. Thesolution was stirred while heating at 100 ± 2 C for 6 h in around-bottom flask, while a slow stream of N2 gas was introduced to the solution by a gas dispersion tube for purging. Fresh DMA was added to maintain the volume and temperature control, but the volume of the reaction mixture was allowed to be reduced to approximately 10 mL by the end of the reaction. After the orange solution obtained was cooled to room temperature (r.t.), it was poured into 90 mL of 1/1 v/v hexane/ethyl acetate and was storedat 15 C overnight. The clear solution was decanted and discardedand an orange oil was obtained when it was warmed to r.t. The orange oil was dissolved with 8 mL of water and the mixture was allowed to stand for 30 min at r.t. to allow complete precipitationof a small amount of unreacted cisplatin. The mixture was then filtered via vacuum filtration; the filtrate contained Et4N[PtCl3NH3].The filtrate solution was stirred with 2.0 g of rinsed Dowex 50-W-X8H+ cation exchange resin for 1 h, the resin was filtered via vacuum filtration, and the volume of the filtrate reduced to approximately 5 mL at r.t. To the yellow/orange filtrate, 0.6 mL of saturated KCl solution was added and the mixture stored and leftto evaporate in the refrigerator (7 C) to slowly obtain orange crystals. Orange crystals collected: 162.9 mg (29.2% yield). |
In N,N-dimethyl acetamide; at 100℃; for 8h; | First, potassium trichloroplatinate(II) was synthesized from cisplatin,which was previously obtained from potassium tetrachloroplatinate(II),according to already described procedures [30]. For this, cisplatin and<strong>[56-34-8]tetraethylammonium chloride</strong> (2 equivalents each) were dissolved in86 mL dimethylacetamide (DMA)/g cisplatin. The reaction mixture washeated at 100 C for 8 h in the dark, under stirring and bubbling N2.During this time, the color of the solution changes fromyellowto orange.Next, the volume was reduced to 30 mL. After cooling, this orange solutionwas added to 500 mL of a hexane/ethyl acetate (1:1) mixture, andthe final solution was maintained overnight at -18 C. After that time,a transparent liquid was decanted and the remaining oil was stirredwith 20 mL of cold water, in order to precipitate the unreacted cisplatin,that was filtered subsequently. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
90% | at 75℃; for 5h; | 0099] Synthesis of c,c,MPt(NH3)2Cl2(OH)2] : Hydrogen peroxide (30 wt%, 60 mL) was added drop wise to a round bottom flask containing <strong>[15663-27-1]cisplatin</strong> (1.0 g, 3.33 mmol). The reaction mixture was heated to 75 C for 5 h. The bright yellow solution was kept at room temperature in the dark for overnight to allow crystallization of the product. Yellow crystals were separated by filtration, washed with cold water and dried to get 1 g of compound. Yield 90%>. IR (KBr) umax (cm-1): 3803 (w), 3515 (w), 3458 (br, OH), 3269 (w), 1582 (s), 1442(s), 1378(s), 1074 (m, Pt-OH), 860 (br), 542 [br, Pt-N(O)]. HRMS m/z Calcd. for Cl2H9N202Pt: (M+H)+ 333.9689. Found 333.9683. Melting Point: 295-300 C. |
90% | at 75℃; under 760.051 Torr; for 5h; | Synthesis of Hydrogen peroxide (30 wt%, 60 mL) was added drop wise to a round bottom flask containing <strong>[15663-27-1]cisplatin</strong> (1.0 g, 3.33 mmol). The reaction mixture was heated to 75 C for 5 h. The bright yellow solution was kept at room temperature in the dark for overnight to allow crystallization of the product. Yellow crystals were separated by filtration, washed with cold water, and dried to get 1 g of compound . . i-l Pt{ M Phi( '(OS I ) ·· I. Yield 90%. IR (KBr) vniax (cm"1): 3803 (w), 3515 (w), 3458 (br, OH), 3269 (w), 1582 (s), 1442(s), 1378(s), 1074 (m, Pt-OH), 860 (br), 542 [br, Pt-N(O)]. HRMS m/z Calcd. for Chi I VO : (M I f ) 333.9689. Found 333.9683. Melting Point: 295-300C. |
87% | In water; at 60℃; for 12h; | Hydrogen peroxide (30?wt%, 30?mL) was added drop wise to a round bottom flask containing <strong>[15663-27-1]cisplatin</strong> (500.0?mg, 1.67?mmol). The reaction mixture was heated to 60?C for 12?h.The bright yellow solution was kept at room temperature in the dark for overnight to allow crystallization of the product. Yellow crystals were separated by filtration, washed with cold water, and dried to get 485.0?mg of oxoplatin, yield 87%. |
75% | With water; at 75℃; for 8h; | In certain embodiments, A-platin is synthesized and purified according to the following (also shown schematically in FIG. 3). Oxoplatin is synthesized from <strong>[15663-27-1]cisplatin</strong> by incubating with hydrogen peroxide for 8 hrs. and purified by precipitating with ice-cold acetone (Yield?75%). 2) Cisplatin-monosuccinate is synthesized by reacting oxoplatin with succinic anhydride in DMSO and precipitated with ice-cold acetone (yield?80%). 3) Subsequently, Cisplatin succinate, and triethylamine is incubated in DMSO for 20 min, and then, N,N?-Dicyclohexylcarbodiimide (DCC) will be added and stirred for 1 hr. To this reaction mixture, Boc-4-Amino-L-phenylalanine is added and stirred overnight. The solid is precipitated and washed three times with ice cold acetone. 4) The Boc group is removed from AT-Platin-Boc by reacting with 10% trifluroacetic acid (TFA) in methanol. 5) AT-Platin is further purified by Flash-chromatography with Hexane-Ethyl acetate gradient. The foregoing method consistently yields AT-Platin up to 96% purity. NMR analysis of <strong>[15663-27-1]cisplatin</strong> and AT-platin are shown in FIG. 1. A mass spectrometric analysis of AT-platin is shown in FIG. 2. |
60% | In water; at 60℃; | General procedure: The carbohydrate-conjugated mono-functionalized platinum(IV) prodrugs (B1-B10) were prepared by the reaction of an amide bond from peracetyl rhamnose, mannose and galactose with a propyl amino or ethyl amino linker at the reducing end and a carboxylic function in the Pt(IV) complexes (B11 and B12) (Scheme 2). The key step involved the preparation of oxoplatin B13 and B14 which was reacted successively in water (12mL) with <strong>[15663-27-1]cisplatin</strong> (0.2g) or oxaliplatin (0.2g) and H2O2 (20mL) at 60C with the yield of 60% and 55% respectively. B11 and B12 were prepared from oxoplatin B13 (1equiv) or B14 (1equiv) and succinic anhydride (1equiv) in anhydrous DMSO at room temperature overnight. DMSO was removed under vacuum to afford a yellow oil and the product was washed with acetone and diethylether, and dried in vacuum. The target compounds B11 and B12 were obtained as a pale yellow solid after purification by recrystallization with the yield of 75% and 78% respectively. Finally, to a solution of B11 or B12 (1equiv) in DMF was added a DMF solution containing HATU. The mixture was stirred for 10minat room temperature. A DMF solution containing amines and DIPEA was added to the resulting solution to obtain B1 to B10 in yields of 20-50%, respectively. The mixture was stirred at room temperature for 24h in the dark. The product was characterized using 1H-NMR, 13C-NMR, ESI-MS spectrometry and elemental analysis (see ESI+). And meanwhile, the synthesis methods of A4 and A5 which have been reported by our group recently with an increasing antitumor activities and a potential safety compared with <strong>[15663-27-1]cisplatin</strong> and oxaliplatin are also listed in Scheme 2. |
at 20℃; for 5h;Darkness; | Cisplatin (600 mg, 2 mmol) was placed in a reaction flask,Add 30% hydrogen peroxide 10mL, dark at room temperature for 5h,The hydrogen peroxide was removed by filtration to give a yellow powder of Cisplatin (IV) (NH3) 2- (OH) 2. | |
In water; at 70℃; for 2h;Inert atmosphere; | In a 150 mL round-bottom flask, 3 g of <strong>[15663-27-1]cisplatin</strong>, 75 mL of deionized water, and 11.4 mL of hydrogen peroxide (30%) were added, and the reaction was carried out at 70 C. for 2 h under argon atmosphere.The precipitated product was cooled with ice water, filtered by suction, washed with ice water, ethanol, and diethyl ether in that order and dried to give c, c, t-[Pt(NH3)2Cl2(OH)2], denoted as Pt(IV)-(OH). )2-1. | |
In water; at 60 - 70℃; for 4h; | oxidizing the compound divalent platinum compound <strong>[15663-27-1]cisplatin</strong> Cis. by hydrogen peroxide at 60 to 70 C,After reacting for 4 hours, a tetravalent <strong>[15663-27-1]cisplatin</strong> compound Oxide-Cis. can be prepared;Dissolving the tetravalent <strong>[15663-27-1]cisplatin</strong> compound Oxide-Cis. (1equiv) and palmitic anhydride (4equiv) in DMF,After reacting at 70 C under nitrogen atmosphere for overnight, the oil pump was drained, and after adding methylene chloride to precipitate a solid,The compound Cis(IV)-COOH can be prepared by washing with chloroform, diethyl ether or the like;Mixing the solution of Cis(IV)-COOH in DMF with 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate in DMF for 10 minutes. after that,Further, a mixture of peracetylated glucosamine and N,N-diisopropylethylamine in DMF was added, and the mixture was reacted at room temperature for 24 hours to obtain 5f1.5f1 was dissolved in an appropriate amount of methanol, and 4M HCl was slowly added dropwise for 48 hours to remove the Boc protecting group to obtain the final product. | |
In water; at 75℃; for 5h; | H2O2 (60 mL, 30% w/v) was added to cisdiamminedichloroplatinum(II) (1 g, 3.3 mmol). The mixturewas stirred for 5 h at 75 C. The resulting yellow solutionwas kept overnight to crystallize. The precipitate was filteredand washed with cold water, ethanol, and diethyl ether, thendried in vacuum. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
76.2% | With hydrogenchloride; In acetonitrile; for 2h;Reflux; | As shown in the above chemical formula,Weigh 60 mg of <strong>[15663-27-1]cisplatin</strong> (0.2 mmol),Add to 6mL of dilute hydrochloric acid pH 4,Add 2 mL of acetonitrile to the solution.Stir well.Heat the solution back to reflux,Until the yellow suspension became a colorless, clear solution (2h).The solution was spun dry to a yellow solid residue.The solid residue solution was treated with 3 mL of dry anhydrous methanol.A yellow suspension was obtained.The solution was filtered through a microporous membrane.The filtrate was slowly dropped into 60 mL of dry anhydrous ether.A large amount of white precipitate is formed.Stir the suspension for 2 h.filter,The filter cake was washed with a small amount of ether.Vacuum drying,A white solid powder P1' is obtained,52 mg, yield 76.2%. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
85.6% | Ampyplatin was prepared from <strong>[15663-27-1]cisplatin</strong> using a literature method [24]. Cisplatin (225mg) was dispersed in double distilled H2O (4mL) with ultrasound for 2min. 3M pyridine (750muL) was added and the suspension heated at 60C for 4h with stirring. After cooling down to room temperature, 10M HCl (1mL) was added and the mixture was kept at 80C overnight with stirring. Yellow, needle shaped crystals precipitated at the bottom of the flask. The solution was cooled to 4C for half an hour to allow further precipitation of crystals. The crystals were collected, washed twice with water and ethanol, and dried under vacuum. The total yield of trans-[PtCl2(NH3)(py)] was 232.5mg (85.6%). 15N labeled trans-[PtCl2(15NH3)(py)] was prepared by the same procedure starting from 15N labeled <strong>[15663-27-1]cisplatin</strong>. The 1H-NMR spectrum recorded in d6-acetone shows signals at 8.87 (m, H2 and H6), 7.98 (m, H4), 7.45 (m, H3 and H5), and 3.74ppm (broad, NH3). Elemental analyses for trans-[PtCl2(NH3)(py)] (PtC5Cl2H8N2). Calculated: C, 16.58; H, 2.23; N, 7.74%. Found: C, 16.9; H, 2.76; N, 7.82%. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
3 g | (1) raw materials (1) cis-diaminodichloroplatinum (5.0 g, 0.017 mol),Tetraethylammonium (3.57 g, 1.2 times equivalent) was dissolved in 130 mL of dimethylacetamide and heated under inert gas protection at 105 C for 12 hours.After distilling the solution under reduced pressure to 50 mL,Add 300 mL of cyclohexane and ethyl acetate (1: 1),The suspension was stored at -12 C for 12 hours.The precipitated crystals were filtered and dried under vacuum to give the crude product as an orange solid.Add 50 mL of deionized water, stir at 25 C for 30 minutes, and then filter.The obtained filtrate was put into Dowex 50W-X8 hydrogen ion exchange resin and stirred for 1 hour, and then the filtrate and solid resin were separated by filtration, and the filtrate was concentrated to 5 mL. At 0 C, 2 mL of a saturated potassium chloride solution was added to the concentrated filtrate, and the mixture was stirred at this temperature for 2 hours to obtain the product compound 2 potassium trichloromonoammonium platinum (II) acid (3.0 g). | |
3 g | Raw material 1 cis-diaminodichloroplatinum (5.0g, 0.017mol),Tetraethylammonium (3.57g, 1.2 times equivalent)Dissolved in 130mL dimethylacetamide,And heated under inert gas at 105 C for 12 hours,After the solution was distilled under reduced pressure to 50 mL, 300 mL of cyclohexane and ethyl acetate (1: 1) were added thereto, and the suspension was stored at -12 C for 12 hours. The precipitated crystals were filtered and dried under vacuum to give the crude product as an orange solid.Add 50 mL of deionized water, stir at 25 C for 30 minutes, and then filter. The obtained filtrate was put into Dowex 50W-X8 hydrogen ion exchange resin and stirred for 1 hour, and then the filtrate and solid resin were separated by filtration, and the filtrate was concentrated to 5 mL. At 0 C, 2 mL of a saturated potassium chloride solution was added to the concentrated filtrate, and the mixture was stirred at this temperature for 2 hours to obtain the product compound 2 potassium trichloromonoammonium platinum (II) acid (3.0 g). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In water; at 60℃; | Example 1; Synthesis of JP09161.; Weigh cisplatin (mw 300) (2 m mole or 600 mg) and place in 150 ml DI water. Mix continuously at ca. 60 C. till cisplatin is all dissolved. 2. Weigh ligand 2 (<strong>[19668-85-0]3-methyl-5-isoxazoleacetic acid</strong>, mw 141.12) (2 m mole or 282 mg) and gradually add it the cisplatin solution until it is all dissolved. Continue heating and mixing for 2 hr. Adding 0.1 N NaOH to raise the pH to about 6 can increase the yield. 3. Cool the aliquot and filter off the precipitate. 4. Reduce the filtrate volume under vacuum to ca. 10-20 ml and a lot of nice yellow needle-like crystals appear. 5. Filter and keep the crystals, and let the crystals dry in air. 6. Use diluted HCl to recrystallize and obtain the pure product (herein after compound JP0916). Note: All containers must be clean and rinsed with deionized water before use. All steps should be conducted under yellow light as much as possible. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
38% | With barium hydroxide octahydrate; silver sulfate; In methanol; water; at 20℃; for 78h; | <strong>[15663-27-1]cisplatin</strong> (600 mg) were suspended in 25 mL water and 624 mg Ag2SO4 were added with stirring. After being stirred at room temperature for 24 h, the precipitates were removed by filtration. The obtained filtrate was mixed with a methanolic solution (20 mL) containing 375 mg HNPAC. Then, an aqueous solution prepared by dissolving 599 mg Ba(OH)2·8H2O in 20 mL water was added dropwise into the mixture in 6 h with stirring. After stirring in dark at room temperature for 48 h, the precipitate was removed by filtration and 50 mL methanol was added. Then, the solvents were removed in vacuo and the residue was washed by methanol and acetone in sequence. NMPt (310 mg) was obtained as pale yellow powders with a yield of 38%. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
59.4% | To a solution of <strong>[15663-27-1]cisplatin</strong> (0.30 g, 10 mmol) in 15 mL DMF was added AgN03 (0.169 g, 1 equiv) and the reaction was stirred under protection from light at 60 C. After 16 h, a AgCl precipitate was filtered. To the supernatant, phenanthridine (0.161 g, 0.9 equiv) was added, and the reaction was stirred for 16 h at 60 60 C. The reaction mixture was evaporated under reduced pressure, and the residue was dissolved in 30 mL of MeOH. Unreacted yellow <strong>[15663-27-1]cisplatin</strong> was removed by filtration. The filtrate was stirred vigorously and diethylether (100 mL) was then added to precipitate the desired compound as a solid. The diethylether and methanol were decanted and washed 2 times with 50 mL of diethylether. The compound was purified by redissolving it in methanol and precipitating it by adding the methanol solution dropwise to vigorously stirred diethyl ether. The final compound was isolated by vacuum filtration and dried in vacuo. X-ray quality crystals were obtained from methanol/diethylether. White solid. Yield: 59.4% (0.30 g). ESI-MS m/z calculated (M+): 443.06, found: 443.1. 1H NMR (DMSO-d6): delta 4.43 (3H, broad), 4.60 (3H, broad), 7.93 (2H, q), 8.02 (1H, t), 8.14 (1H, t), 8.46 (1H, d), 8.93 (2H, q), 9.78 (1H, d), 9.95 (1H, s). 13C NMR (DMSO-d6): delta 122.53, 123.27, 125.23, 126.20, 129.02, 129.36, 130.17, 131.72, 134.24, 142.39, 160.14. 195Pt NMR (DMSO-d6): delta -2298.51. Anal. Calcd. for Ci3H15ClN403Pt: C, 30.87; H, 2.99; N, 11.08; Found: C, 31.08; H, 3.02; N, 11.03. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
60% | The complex cis-[PtI2(NH3)2] (0.82 mmol, 400 mg) was dissolved in 50 mL of distilled water at 80 C and 2 molar equiv. of AgNO3(280 mg) was added. After 20 min of stirring of the reaction mixture in the dark (under aluminiumfoil), the formed precipitate was filtered off and the obtained filtrate was concentrated to the volume of ca. 5 mL. Anexcess of KCl (13.3 mmol, 990 mg) was added to the concentrated solution at 0 C, leading to the immediate precipitation of the yellow solid of cis-[PtCl2(NH3)2] (cisplatin),which was collected after 15 min of stirring at 0 C. Theproduct was washed by EtOH (3 mL) and DEE (2 × 3 mL),and dried under vacuum (1 h). The yield was ca. 60% (calculatedto cis-[PtI2(NH3)2]). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
87% | An aqueous solution of cis-diamminedichloro platinum (0.055 g, 0.19 mmol) and silver nitrate (0.047 g, 0.28 mmol) in 10 mL deionised water was stirred in the dark for 24 h. As soon as the two salts were added together, the precipitation of silver chloride occurred. The precipitate was however filtered after 24 h of reaction. The filtrate was collected and mixed with a solution of the sodium salt of Al(OH)OCPc (0.052 g, 0.045 mmol). The ratio of Al(OH)OCPc to the Pt complex was 1:3. The solution was stirred for 4 h at 55 C, following literature methods [2,3]. The solution was allowed to stand for 12 h and the precipitate was collected. The conjugate was washed with water, ethanol, acetone and diethyl ether. Yield 0.063 g (87%). IR (KBr, cm-1): 3436 (OH), 3125 (NH), 1712 (C=O), 1699, 1560 1437, 1347. UV-Vis (PBS): lambdamax log epsilon: 359 (4.22), 630 nm (4.65), 699 (5.23) nm. 1H NMR (D2O): delta = 8.6 (8H, broad, Ar-H), delta = 2.7 (18H, broad, NH3). Calc. for Na2C40H27N14O17AlPt3: C, 29.71; N, 12.00; H, 2.41. Found: C, 30.32; N, 11.57; H, 3.56%. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
28% | Cisplatin (500mg, 1.67mmol) and AgNO3 (552mg, 3.25mmol) were stirred in 10ml H2O in the absence of light at room temperature for 16hr. The resulting mixture was filtered to remove AgCl. To the filtrate, a solution of NaOH (67mg, 1.68mmol) and succinylacetone (269mg, 1.70mmol) in 5ml of H2O was added dropwise. After stirring at room temperature (RT) for 5hr, the resulting solution was concentrated to dryness at 60C under reduced pressure to afford an orange oil. This oil was dissolved in 3ml of H2O and acidified with three drops of 25% HNO3. Acetone (50ml) was added, and the resulting turbidwhite suspension was stirred for ?3min, resulting in the deposition of an oily orange-brown residue. The turbid supernatant was decanted and mixed with 50ml of a 1:1 (v/v) mixture of acetone and diethyl ether. Upon stirring at RT for ?5min, an orange-brown residue deposited again. The cloudy supernatant was decanted and poured directly into 150ml of diethyl ether. The mixture was stored at -40C for 1.5hr and filtered to collect a whitesolid. The white solid was washed with 2× 10ml diethyl ether and then dried in vacuo. The yield equals 203mg (28%). Characterization data are given in Note S1A. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
60% | To a solution of cisplatin (0.15 g, 0.5 mmol) in DMF (5 mL) was added AgNO3 (0.085 g, 0.5 mmol), and the reaction was stirred under protection from light at room temperature. After 16 hours, AgC1 precipitate was removed by filtration. <strong>[605-03-8]<strong>[605-03-8]4-phenylquinol</strong>ine</strong> (0.1 g, 0.5 mmol) was added to the filtrate, and the reaction was stirred for 16 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in 30 mL methanol. Unreacted yellow cisplatin was removed by filtration.The filtrate was purified by prep-HPLC (eluting with CH3CN/dilute HCl) to afford compound 4 as a white solid (120 mg, 60% yield). 1H NMR (500 MHz, DMSO): delta 9.72 (d, J = 8.0 Hz, 1H), 9.30 (d, J = 6.0 Hz, 1H), 8.09 (t, J = 8.0 Hz, 1H), 7.96 (d, J = 8.0 Hz, 1H), 7.80 (t, J = 8.0 Hz, 1H), 7.65-7.5 8 (m, 6H), 4.60 (s, 3H), 4.44 (s, 3H). LC-MS m/z: 468 (M+). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
60% | To a solution of <strong>[15663-27-1]cisplatin</strong> (0.15 g, 0.5 mmol) in DMF (5 mL) was added AgNO3 (0.085 g, 0.5 mmol), and the reaction was stirred under protection from light at room temperature. After 16 hours, AgC1 precipitate was removed by filtration. 6-Bromoquinoline (0.1 g, 0.5 mmol) was added to the filtrate, and the reaction was stirred for 16 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in 30 mL methanol. Unreacted yellow <strong>[15663-27-1]cisplatin</strong> was removed by filtration. The filtrate was purified by prep-HPLC (eluting with CH3CN/dilute HC1) to afford compound 5 as a white solid (150 mg, 60% yield). 1H NMR (500 MHz, DMSO): delta 9.49 (d, J = 8.5 Hz, 1H), 9.32 (d, J = 5.0 Hz, 1H), 8.64 (d, J = 8.5 Hz, 1H), 8.49 (d, J = 2.0 Hz, 1H), 8.21 (dd, J = 8.5 Hz,2.0 Hz, 1H), 7.74 (dd, J = 8.5 Hz, 5.0 Hz, 1H), 7.59-7.56 (m, 2H), 7.50-7.49 (m, 1H), 4.68 (s, 3H),4.51 (s, 3H). LC-MS m/z: 471 (M+). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
60% | To a solution of <strong>[15663-27-1]cisplatin</strong> (0.15 g, 0.5 mmol) in DMF (5 mL) was added AgNO3 (0.085 g, 0.5 mmol), and the reaction was stirred under protection from light at room temperature. After 16 hours, AgC1 precipitate was removed by filtration. 6-phenylquinoline (0.1 g, 0.5 mmol) was added to the filtrate, and the reaction was stirred for 16 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in 30 mL methanol. Unreacted yellow <strong>[15663-27-1]cisplatin</strong> was removed by filtration. The filtrate was purified by prep-HPLC (eluting with CH3CN/dilute HCl) to afford compound 6 as a white solid (150 mg, 60% yield). 1H NMR (500 MHz, DMSO): delta 9.62 (d, J = 8.5 Hz, 1H), 9.26 (d,J 5.0 Hz, 1H), 8.71 (d,J 8.5 Hz, 1H), 8.46 (d,J 1.5 Hz, 1H), 8.39 (dd,J= 8.5 Hz,1.5 Hz, 1H), 7.89 (d, J = 8.5 Hz, 2H), 7.71 (dd, J = 8.5 Hz, 5.0 Hz, 1H), 7.59-7.56 (m, 2H),7.50-7.49 (m, 1H), 4.70 (s, 3H),4.50 (s, 3H). LC-MS m/z: 469 (M+) |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
45% | To a solution of <strong>[15663-27-1]cisplatin</strong> (0.15 g, 0.5 mmol) in DMF (5 mL) was added AgNO3 (0.085 g, 0.5 mmol), and the reaction was stirred under protection from light at room temperature. After 16 hours, AgCl precipitate was removed by filtration. 7,8,9,10- tetrahydrophenanthridine (0.091 g, 0.5 mmol) was added to the filtrate, and the reaction was stirred for 16 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in 20 mL methanol. Unreacted yellow <strong>[15663-27-1]cisplatin</strong> was removed by filtration. The filtrate was purified by prep-HPLC (eluting with CH3CN/dilute HCl) to afford compound 7 as a white solid (110 mg, 45% yield). 1H NMR (500 MHz, DMSO): delta 9.53 (d, J = 8.0 Hz, 1H), 9.04 (s, 1H), 8.13 (d, J = 8.0 Hz, 1H), 7.92 (t, J = 8.0 Hz, 1H), 7.75 (t, J= 8.0 Hz, 1H), 4.64 (s, 3H), 4.44 (s, 3H), 3.23-3.14 (m, 2H), 2.99-2.87 (m, 2H), 1.93-1.85 (m, 4H). LC-MS m/z: 447 (M+). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
56% | To a solution of <strong>[15663-27-1]cisplatin</strong> (0.15 g, 0.5 mmol) in DMF (5 mL) was added AgNO3 (0.085 g, 0.5 mmol), and the reaction was stirred under protection from light at room temperature. After 16 hours, AgCl precipitate was removed by filtration. 1,2,3,4-Tetrahydrophenanthridine (0.091 g, 0.5 mmol) was added to the filtrate, and the reaction was stirred for 16 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in 20 mL methanol. Unreacted yellow <strong>[15663-27-1]cisplatin</strong> was removed by filtration. The filtrate was purified by prep-HPLC (eluting with CH3CN/dilute HCl) to afford compound 8 as a white solid (140 mg, 56% yield). 1H NMR (500 MHz, DMSO): delta 9.62 (s, 1H), 8.25 (d, J = 8.0 Hz, 1H), 8.08 (d, J = 8.0 Hz, 1H), 7.94 (t, J = 8.0 Hz, 1H), 7.77 (t, J = 8.0 Hz, 1H), 4.64 (s, 3H), 4.37 (s, 3H), 3.81-3.70 (m, 2H), 3.13-3.08 (m, 2H), 1.96-1.85 (m, 4H). LC-MS m/z: 447 (M+). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
60% | To a solution of <strong>[15663-27-1]cisplatin</strong> (0.15 g, 0.5 mmol) in DMF (15 mL) was added AgNO3 (0.085 g, 0.5 mmol), and the reaction was stirred under protection from light at room temperature. After 16 hours, AgC1 precipitate was removed by filtration. 3-bromoquinoline (0.1 g, 0.5 mmol) was added to the filtrate, and the reaction was stirred for 16 hours at room temperature. The reaction was concentrated under reduced pressure, and the resulting residue was dissolved in 30 mL methanol. Unreacted yellow <strong>[15663-27-1]cisplatin</strong> was removed by filtration. The filtrate was purified by prep-HPLC (eluting with CH3CN/dilute HCl) to afford compound 2 as a white solid (150 mg, 60% yield). 1H NMR (500 MHz, DMSO): delta 9.53 (d, J = 8.5 Hz, 1H), 9.42 (d, J = 2.0 Hz, 1H), 9.09 (s, 1H), 8.12-8.07 (m, 2H), 7.86 (d, J = 8.5 Hz, 1H), 4.56 (s, 3H),4.47 (s, 3H). LC-MS m/z: 472 (M+). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
89% | In water; for 2h;Reflux; | a solution of thiosaccharinate (0.26 g, 1.33 mmol) in hot water (30 cm3) was added to a solution of cis-[PtCl2(NH3)2] (0.20 g, 0.667 mmol) in hot water (15 cm3). The mixture was reuxed for 2 h. The light-brown solid formed was ltered off washed several times with distilled water and dried in vacuo. Yield: 89% (0.39 g). Anal. Calcd. for C14H14N4O4PtS4: C, 26.88; H, 2.26; N,8.96. Found: C, 26.33; H, 2.09; N, 8.86%. IR (KBr) (nu, cm-1): 3471 m, 3413 m, 3286 m, 1627s,1440w, 1373s, 1315s, 1236 m, 1155 m, 1126s, 1008w, 817 s, 515 m. 1H NMR (d6-DMSO): 7.96-7.90 (m, 4H), 7.82-7.75 (m, 4H), 4.54 (s, 6 H). 13C{1H} NMR (d6-DMSO): 182.8, 137.6,133.7, 133.4, 133.1, 124.3, 120.7 ppm. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
6.08% | The cisplatin intermediate was prepared as follows. Cis-dichlorodiamine Pt (II) (240 mg, 0.8 mmoles) (Sigma) was suspended in 30 ml distilled water and heated to 70 C to dissolve the complex. The solution was then cooled to RT. Thereafter, aqueous solution of silver nitrate ((135.9 mg, 0.8 mmoles) in 10 ml of water) was added drop-wise to the solution of starting material under stirring (400 rpm). The formation of translucent white precipitate of silver chloride was commenced immediately after the addition of the aqueous solution. The mixed solution was stirred for 3 hr at RT under light shielding conditions. The resulting precipitate of silver chloride was filtered off (Corning polystyrene Filter System, Corning) (0.22 tM) and washed with water. The combined filtrate was used in the following step without further treatment.[0098] The Pt (II) monostearate complex was prepared as follows. To an aqueous solution of <strong>[822-16-2]sodium stearate</strong> ((245.15 mg, 0.8 mmoles) (Sigma) in 10 ml of water) was added the aqueous solution obtained above and stuffed at RT for 3 weeks under light shielding conditions to complete the reaction. The translucent white precipitate formed was filtered off, washed with a small amount of ether, and dried in vacuum desiccator to obtain the crude product. [0099] Because the crude product contained a mixture of mono- and di-fatty acid platinum derivatives, and the mono-fatty acid platinum derivative was soluble in chloroform, chloroform was used to purify the mixture. The crude product was suspended in 25 ml chloroform in conical tube, vortex mixed for 5 mm, and kept at RT for 24 hr. Tubes were then centrifuged (5000 rpm, 10 mm) (Beckman Coulter, Inc.), and the supernatant was carefully transferred into glass vials and vacuum dried to obtain the Pt-MSA complex (yield = 6.08%). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
6.08% | The cisplatin intermediate was prepared as follows. Cis-dichlorodiamine Pt (II) (240 mg, 0.8 mmoles) (Sigma) was suspended in 30 ml distilled water and heated to 70 C to dissolve the complex. The solution was then cooled to RT. Thereafter, aqueous solution of silver nitrate ((135.9 mg, 0.8 mmoles) in 10 ml of water) was added drop-wise to the solution of starting material under stirring (400 rpm). The formation of translucent white precipitate of silver chloride was commenced immediately after the addition of the aqueous solution. The mixed solution was stirred for 3 hr at RT under light- shielding conditions. The resulting precipitate of silver chloride was filtered off (Corning polystyrene Filter System, Corning, Amsterdam, Netherlands) (0.22 muMu) and washed with water. The combined filtrate was used in the following step without further treatment. [00193] The Pt (II) monostearate complex was prepared as follows. To an aqueous solution of <strong>[822-16-2]sodium stearate</strong> ((245.15 mg, 0.8 mmoles) (Sigma) in 10 ml of water) was added the aqueous solution obtained above and stirred at RT for 3 wk under light- shielding conditions to complete the reaction. The translucent white precipitate formed was filtered off, washed with a small amount of ether, and dried in vacuum desiccator to obtain the crude product. [00194] Because the crude product contained a mixture of mono- and di-fatty acid Pt derivatives, and the mono-fatty acid Pt derivative was soluble in chloroform, chloroform was used to purify the mixture. The crude product was suspended in 25 ml chloroform in conical tube, vortex mixed for 5 min, and kept at RT for 24 hr. Tubes were then centrifuged (5000 rpm, 10 min) (Beckman-Coulter, Inc.), and the supernatant was carefully transferred into glass vials and vacuum dried to obtain the Pt (II) monostearic acid complex (yield = 6.08%). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
75% | With dihydrogen peroxide; In water; at 70℃; for 5h; | Accurately weigh <strong>[15663-27-1]cisplatin</strong> (1.00 g, 3.30 mmol) in a 25 mL round bottom flask, stir into 2 mL of distilled water, and slowly add H2O2 (30% w/v, 10.0 mL) dropwise at 70 C for 5 hours. After completion of the reaction, the reaction solution was cooled to room temperature and then placed at 4 C overnight, then the supernatant was removed by centrifugation to give a pale yellow solid. The solid were washed twice with distilled water, ethanol and ether, and then dried in vacuo to give a pale yellow solid 826.65mg, 75% yield. |
With dihydrogen peroxide; In water; at 20 - 65℃; | Dissolve <strong>[15663-27-1]cisplatin</strong> (2.0 mmol, 600.0 mg) in 35.0 mL of deionized water, add 12.0 mL of 30% hydrogen peroxide (H 2 O 2 ) under magnetic stirring, perform redox reaction at 65 C for 5 h, and then react at room temperature overnight. Filtration of H2O2 to obtain a pale yellow solid, which is cis-diamine dichlorodichloroplatinum (IV); | |
With dihydrogen peroxide; In water; at 20 - 50℃; for 25h; | (1) Ultrasonic disperse 100 mg of <strong>[15663-27-1]cisplatin</strong> (CDDP) in 5 mL of 30% volume H2O2 aqueous solution, react at 50 C for 1 h, then stand for 24 h, then centrifuge and vacuum dry to obtain hydroxylated <strong>[15663-27-1]cisplatin</strong> Compound (CDDP-OH) |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
93.3% | at 70℃; for 5h;Darkness; | The specific synthesis steps are:Weigh 1.2 g of <strong>[15663-27-1]cisplatin</strong> (4.00 mmol) into a 100 mL round bottom flask, add 60 mL of 30% hydrogen peroxide solution, and stir vigorously at 70 C for 5 h in the dark.As the reaction progresses, <strong>[15663-27-1]cisplatin</strong> slowly dissolves,Finally, a transparent yellow solution is formed.After the reaction was completed, a small amount of insoluble material was removed by filtration while hot. After cooling at room temperature, it was left at 4 C overnight to obtain a crystalline precipitate of platinum oxide. Product centrifugation,It was washed once with deionized water and dried under vacuum overnight to obtain a light yellow powder.Yield: 1.26g (93.3%). |
90% | at 4 - 75℃; for 7h;Darkness; | Add CDDP (1 g, 3.33 mmol) to a 100 mL round bottom flaskAnd 15 ml of 30% hydrogen peroxide (30%, w/v).Stir in the dark at 75 C for 5 hours.Cool at 4 C for 2 hours,Light yellow crystals were obtained by filtration under reduced pressure.Use water separately,Wash with ethanol and ether,After drying, product II (998 mg, yield 90%) was obtained. |
85% | In water; for 5h; | This compound was prepared following previously reportedmethods [40]. Hydrogen peroxide (30 wt%, 2.5 mL) was added dropwise to a round bottom flask containing <strong>[15663-27-1]cisplatin</strong> (300 mg,1 mmol).The reaction mixture was heated to 75 C for 5 h. The bright yellowsolutionwas kept at 4 C to afford yellow crystals. The crystals wererecovered by filtration and washed with cold water, ethanol andether. Finally, the product was dried in vacuum. Yield 85% (283 mg,0.85 mmol). Melting Point: 291e294 C. IR (KBr): 3461 (s, OHstretch), 1075 (m, PteOH bend), 539 (m, PteN(O) stretch).Elemental analysis (%): calcd for Cl2H8N2O2Pt: H, 2.41; N, 8.39.Found: H, 2.45; N, 8.53. ESI-HRMS m/z calcd for Cl2H9N2O2Pt: [M H] 333.9611, found 334.2917. |
85% | at 75℃; for 5h; | Hydrogen peroxide (30 wt%, 2.5 mL) was added dropwise to around bottom flask containing <strong>[15663-27-1]cisplatin</strong> (300 mg, 1 mmol). The reaction mixture was heated to 75 C for 5 h. The bright yellow solution was kept at 4 C in the dark to afford yellow crystals. The crystals were recovered by filtration and was washed with cold water, ethanol and ether, and dried in vacuum. Yield 85% (283 mg,0.85 mmol). IR (KBr): 3461(s, OH stretch), 1075 (m, PteOH bend),539 (m, PteN(O) stretch). Melting Point: 291-294 C. Elementalanalysis (%): calcd for Cl2H8N2O2Pt: H, 2.41; N, 8.39. Found: H, 2.45;N, 8.53. HR-MS m/z calcd for Cl2H9N2O2Pt: [M + H]+, 333.9611;found, 334.2917. |
75% | In water; at 60℃; for 4h; | To a 250 mL round-bottom flask, 1.0 g of <strong>[15663-27-1]cisplatin</strong> 6-1, 30 mL of distilled water were added, and stirred to disperse, and 50 mL of hydrogen peroxide with a concentration of 30% was slowly added dropwise to the reaction system, and the temperature was raised to 60 C. to stir for 4 h. The reaction was stopped, and the crystal was left at 4 C for 12 hours. The yellow solid was separated by filtration, added to an appropriate amount of distilled water, heated to 80 C to dissolve it, and crystallized at 4 C for 12 hours. 75%). |
74% | In water; at 60℃; for 4h; | To a 250 mL round-bottomed flask, 1.0 g of <strong>[15663-27-1]cisplatin</strong> and 30 mL of distilled water were stirred and dispersed. 50 mL of 30% hydrogen peroxide was slowly added dropwise to the reaction system, and the temperature was raised to 60 C. and the reaction was stirred for 4 h. Stop the reaction, leave it to crystallize at -4 C for 12 hours, filter to obtain a yellow solid, add an appropriate amount of distilled water, heat to 80 C to dissolve, and crystallize at 4 C for 12 hours. Filter to obtain compound 4a-1 yellow crystals (0.82g , 74%). |
67.2% | In water; at 20℃; for 144h; | (0277) 150 g of <strong>[15663-27-1]cisplatin</strong> is suspended in about 300 ml of water in a 2 liter three-necked flask (provided with precision glass stirrer) and added with 350 ml H202 (35%) in portions with stirring over a period of 2 days. Stirring is continued for another 4 days at about 20C. Thereafter, the raw product is sucked off, washed with a small amount of ice water, dissolved in a precisely sufficient amount of 0,5 N sulphuric acid, and subsequently precipitated with 35% NaOH (pH7-8). After storage in a refrigerator overnight, the yellow crystalline mass is sucked off, washed with a small amount of cold water, ethanol and eventually with ether and dried in vacuum. Yield (3 batches): 336.7g (67.2% of theoretical). |
43% | In water; at 75℃; for 5h; | H2O2 (60 mL, 30% w/v) was added to cis-diamminedichloroplatinum(II) (1 g,3.3 mmol). The mixture was stirred for 5 h at 75 C. The resulting yellow solutionwas kept overnight to crystallize. The precipitate was filtered and washed with coldwater, ethanol and diethyl ether, then dried in vacuum. N-H), 1361, 1039 (s, Pt-O), 902 (s, Pt-Cl), 554 (s, Pt-N). |
at 20℃; for 8h; | Cisplatin (600mg, 2mmol) placed in a flask, and then 30% hydrogen peroxide was added 10mL, After stirring at room temperature for 8 h, filtered to remove the hydrogen peroxide to give Cisplatin (IV) - (OH)2 Yellow powder. | |
at 60℃; | cis-[Pt(NH3)2Cl2(OH)2]was synthesized by treating cis-[Pt(NH3)2Cl2] with a 10% H2O2 solution at 60C [12]. | |
In water; at 65 - 75℃;Darkness; | Preparation of an axially bishydroxy-coordinated tetravalent platinum compound (oxoplatin),Specific steps are as follows:200mg of divalent <strong>[15663-27-1]cisplatin</strong> (CDDP),6 mL of deionized water and 6.5 mL of 30% hydrogen peroxide were added to the 50 mL reaction flask.Reacting at 65-75 C (preferably 70 C) for 10-12 h in the dark,After concentrating by steaming,The ice water is cooled and the product is obtained.Using ice water in turn,Ethanol,The reaction product was washed with diethyl ether and dried under vacuum.An axially bishydroxy-coordinated tetravalent platinum compound Pt(IV)-(OH)2 (oxoplatin) was obtained. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
87% | In brief, cisplatin (0.30 g, 1 mmol), HNO3 (100 mul), andsilver nitrate (0.34 g, 2 mmol) were added into a roundbottomflask containing 50 ml pure water. The reactionmixture was stirred in the dark at room temperature for48 h. The resultant turbid solution was filtered to removewhite silver chloride. To the yellow colored solution,<strong>[2156-56-1]sodium dichloroacetate</strong> (0.36 g, 2.4 mmol) was added toform a precipitate of DCA-Pt(II). The solid was filtered and dried under vacuum. A weight of 0.42 g of the productwas obtained in an 87% yield. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With sodium hydroxide; In water; at 20℃; for 60h; | To the reaction flask 33.69mg <strong>[60-00-4]EDTA</strong> and 70mL water, with 0.1M Of NaOH to adjust pH to 6.8, adding 69.18mg of CDDP. The reaction was stirred 60h at room temperature After using a 500 MWCO dialysis 30h is dialysis bag, liquid is collected, and lyophilized to give Pale yellow crystalline solid, <strong>[60-00-4]EDTA</strong> binuclear platinum complexes. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With sodium hydroxide; In water; at 20℃; for 60.0h;pH 8.2; | To the reaction flask was added 32.73mg dihydrate disodium edetate and 55mL of pure Water, pH adjusted with 0.1M NaOH to 8.2, was added 52.77mg of CDDP. Room temperature After stirring 70h of reaction, with a 500 MWCO dialysis 30h is dialysis bag, liquid is collected, Freeze drying light yellow crystalline solid, EDTA binuclear platinum complexes. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
59.8% | With ethylenediamine; In methanol; water; at 20℃; for 6h; | General procedure: One millimole of ethylenediamine solution was dropped to solution of 1 mmol H2L1 in absolute methyl alcohol (30 mL) to make H2L1 completely dissolved, and then 1 mmol Potassium platinochloride in 3 mL water was dropwise to the resulting solution. Leave the reaction stirring at room temperature for 6 h. The crude product of Pt(II) metal complex C1 was obtained and washed by distilled water, ethanol for three times respectively. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
300 mg of cisplatin and 169.87 mg of silver nitrate were dissolved in 10 mL of DMF, 24 hours after the reaction to remove silver chloride precipitation, the supernatant for the solution one; 42.3 mg of 3,4-dihydroxybenzenamic acid was mixed with 35.3 mg of sodium carbonate in 5 mL of DMF, After the reaction to remove the insoluble material, the supernatant for the solution two; solution 1 and solution two mixed reaction 48h, Removing the organic solvent, dissolving with methanol to remove excess cisplatin, and recrystallizing to obtain an amphiphilic drug-drug complex,Its structure (c) is as follows; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
300 mg of cisplatin and 169.87 mg of silver nitrate were dissolved in 20 mL of water and the silver chloride precipitate was removed after 24 h, Supernatant for the solution three; After adding 332 mg of <strong>[1069-66-5]sodium valproate</strong> to solution three for 48 h,Removal of water, in ether precipitation in the amphiphilic drug - drug complex, the structural formula (d) is as follows: |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
cisplatin and 169.87mg 300mg silver nitrate dissolved in 10mL DMF and the reaction is removed after precipitation of silver chloride 24h, a solution to obtain a supernatant; and 88.1mg 13.3mg <strong>[149647-78-9]vorinostat</strong> with a sodium hydroxide dispersion in 5mL of methanol, insolubles were removed after the reaction to give a supernatant solution II; a solution and mixing two reaction solution 48h, the organic solvent is removed, dissolved in methanol to remove excess cisplatin, recrystallized amphiphilic drugs - drug complexes having the formula (a) below |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
60% | With sodium carbonate; silver nitrate; In N,N-dimethyl-formamide; at 20℃; for 24h;Darkness; | 150 mg of <strong>[15663-27-1]cisplatin</strong>), AgNO3 (170 mg), Mesalazine (76.6 mg) and Na2C03 (35.3 mg) were added into a round-bottom flask followed by addition of 10 ml of DMF and stirring at room temperature for 24 h. The AgCl precipitate was discarded by filtration, Concentrated by centrifugation, added with 50 ml of ethyl acetate, and then washed three times with 50 ml of 0.1 M Na2CO3 and washed with water three times. The ethyl acetate layer was collected and dried over anhydrous sodium sulfate overnight. Filtration, the filtrate with methanol: chloroform = 1: 9 eluent, silica gel column chromatography to obtain <strong>[15663-27-1]cisplatin</strong> - Mesalazine complex, the yield of 60%, the structural formula shown in Figure 50. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
60% | With sodium carbonate; silver nitrate; In N,N-dimethyl-formamide; at 20℃; for 24h;Darkness; | isplatin (I50 mg), AgNO3 (170 mg), tolfenamic acid (131 mg) and Na2C03 (35.3 mg)Add a round bottom flask, Then 10 ml of DMF was added and stirred for 24 h at room temperature in the dark.AgCl precipitate was discarded by centrifugation, the filtrate was concentrated after adding 50ml of ethyl acetate, and then washed with 50ml 0.1M Na2C03 three times, washed three times,The ethyl acetate layer was collected and dried over anhydrous sodium sulfate overnight.Filtration, the filtrate with methanol: chloroform = 1: 9 eluent,The compound of cisplatin-tolfenamic acid was isolated by silica gel column chromatography with a yield of 60%. The structural formula is as shown in formula 1 |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
53% | With sodium carbonate; silver nitrate; In N,N-dimethyl-formamide; at 20℃; for 24h;Darkness; | Cisplatin (150mg), AgNO3 (170mg), gentisic acid (77mg) and Na2C03 (35.3mg) were added to a round bottom flask followed by 15ml of DMF and stirred for 24 h at room temperature in the dark. The precipitate was removed by centrifugation. After the filtrate was concentrated, 50 ml of ethyl acetate was added and the mixture was washed three times with 50 ml of 0.1 M Na2CO3 and washed with water three times. The ethyl acetate layer was collected and dried over anhydrous sodium sulfate overnight. Filtration, the filtrate with methanol: dichloromethane = 1: 9 eluent, silica gel column chromatography to obtain <strong>[15663-27-1]cisplatin</strong> - gentisic acid complex, a yield of 53%, the structural formula is shown in the formula 24.. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
49% | With sodium carbonate; silver nitrate; In N,N-dimethyl-formamide; at 20℃; for 24h;Darkness; | <strong>[15663-27-1]cisplatin</strong> (150 mg), AgN03 (170 mg), olsalazine (75.6 mg) and Na2C03 (70.6 mg) were added to a round bottom flask followed by 15 ml of DMF and stirred for 24 h at room temperature in the dark. The precipitate was removed by centrifugation. After the filtrate was concentrated, 50 ml of ethyl acetate was added and the mixture was washed three times with 50 ml of 0.1 M Na2CO3 and washed with water three times. The ethyl acetate layer was collected and dried over anhydrous sodium sulfate overnight. Filtration and the filtrate was eluted with methanol: dichloromethane = 1: 9 and separated by silica gel column chromatography to give the <strong>[15663-27-1]cisplatin</strong>-olsalazine complex in 49% yield, as shown in Formula 25 |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
53% | With sodium carbonate; silver nitrate; In N,N-dimethyl-formamide; at 20℃; for 24h;Darkness; | Add <strong>[15663-27-1]cisplatin</strong> (150mg), AgN03 (170mg), fendosal(190.7mg) and Na2C03 (35.3mg) into a round bottom flask, then add 15ml of DMF and stir at room temperature for 24h. The precipitate was removed by centrifugation. After the filtrate was concentrated, 50 ml of ethyl acetate was added and the mixture was washed three times with 50 ml of 0.1 M Na2CO3 and washed with water three times. The ethyl acetate layer was collected and dried over anhydrous sodium sulfate overnight. Filtration, the filtrate with methanol: dichloromethane = 1: 9 eluent, silica gel column chromatography to obtain <strong>[15663-27-1]cisplatin</strong> - Fendalu complex, a yield of 53%, the structural formula is shown in formula 26.. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In water; at 20℃; for 65h;pH 7.5; | 53.28 mg of DTPA and 80 mL of pure water were added to the reaction flask, the pH was adjusted to 7.5 with 0.1 M KOH, and 81.28 mg of CDDP was added. The reaction was stirred at room temperature for 65h, dialyzed against a dialysis bag with molecular weight cut-off of 500 for 48h, and the liquid was collected and stored in a refrigerator at 4 C. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
71.3% | (6) Synthesis of Pt (NH 3) 2 (AtC 2) Cl 2AtC 2 .2 HCl 0.42 g (1.3 mmol)Was dissolved in 10 ml of H 2 0 and 0.20 g (5 mmol) of NaOH was added. 20 mL of CHCl 3 was added to extract AtC 3, evaporated and dissolved in 10 mL of EtOH.To this was added a solution of 0.15 g (0.5 mmol) of Pt (NH 3) 2 Cl 2 in 5 ml of H 2 O, stirred at 60 C. for 24 hours, evaporated until the filtrate reached 1 to 2 ml, reprecipitated with acetone, Was collected by suction filtration, washed, and dried.Yield: 0.212 gYield: 71.3% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
61.7% | With silver nitrate; In N,N-dimethyl acetamide; water; at 60℃;Darkness; | (2) Synthesis of cis-Pt (NH 3) 2 Cl 20.68 g (4.0 mmol) of AgNO 3 was dissolved in 80 ml of H 2 O,A solution of 10 ml of dimethylacetamide in which 0.96 g (2.0 mmol) of cis-Pt (NH 3) 2 I 2 was dissolved was added, and the mixture was shielded from light and stirred overnight. The solution was filtered to remove AgI and washed with 1 M2 mL of NaCl was added,And the mixture was stirred at 60 C. overnight.The produced yellow powder was collected by filtration,With a lot of cold waterAnd washed.Yield: 0.374 gYield: 61.7% |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
62.3% | The <strong>[15663-27-1]cisplatin</strong>-containing prodrug ligand (PtH6N2Cl2, 38.7 mg, 0.129 mmol) was dissolved in 3 mL of N,N-dimethylformamide, silver nitrate (22 mg, 0.129 mmol) was added, and the reaction was carried out at 60 degrees for 24 hours. The precipitate was removed by filtration; the tin porphyrin core (24.8 mg, 0.032 mmol) was suspended in 3 mL of N,N-dimethylformamide, and the above reaction solution was added dropwise to the suspension, nitrogen.The reaction was carried out under gas protection for 36 hours. Precipitation with diethyl ether, filtration, washed with cold methanol, chloroform and diethyl ether to afford title product. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
45% | General procedure: The general synthetic procedure for the mixed transplatinum(II) complexes has been reported by Wilson and Lippard [4]. Cisplatin (100 mg, 0.333 mmol) was suspended in water (2 mL), and 8 equivalents of the appropriate alkylamine ligand were added. The resulting mixture was heated at 90 C until the solution became colourless. After the solution was cooled to room temperature, it was then treated with 37% (v/v) concentrated HCl (2.5 mL) followed by stirring and heating at 90 C for 48 h. The resulting yellow solution was placed in an iced bath to induce precipitation of the appropriate trans-platinum(II) complex which was recovered by filtration, washed intensively with water and diethyl ether, and air-dried at room temperature. tPt2 yield: 49 mg (45%). 1H NMR (500 MHz, DMF-d7), delta(ppm): 1.26 (t, 3H); 2.73 (sextet 2H); 3.72 (s, 3H), 4.38 (s, 2H). 195Pt NMR (107 MHz, DMF-d7), delta(ppm): - 2165.7. TOF MS/ES+, m/z: (M + Na)+: 350.9 (C2H8NaN2PtCl2, species). Anal. Cal for C2H10N2PtCl2: N, 8.54; C, 7.32; H, 3.07. Found: N, 8.50; C, 7.00; H, 2.86. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
80% | General procedure: The general synthetic procedure for the mixed transplatinum(II) complexes has been reported by Wilson and Lippard [4]. Cisplatin (100 mg, 0.333 mmol) was suspended in water (2 mL), and 8 equivalents of the appropriate alkylamine ligand were added. The resulting mixture was heated at 90 C until the solution became colourless. After the solution was cooled to room temperature, it was then treated with 37% (v/v) concentrated HCl (2.5 mL) followed by stirring and heating at 90 C for 48 h. The resulting yellow solution was placed in an iced bath to induce precipitation of the appropriate trans-platinum(II) complex which was recovered by filtration, washed intensively with water and diethyl ether, and air-dried at room temperature. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
75% | General procedure: The general synthetic procedure for the mixed transplatinum(II) complexes has been reported by Wilson and Lippard [4]. Cisplatin (100 mg, 0.333 mmol) was suspended in water (2 mL), and 8 equivalents of the appropriate alkylamine ligand were added. The resulting mixture was heated at 90 C until the solution became colourless. After the solution was cooled to room temperature, it was then treated with 37% (v/v) concentrated HCl (2.5 mL) followed by stirring and heating at 90 C for 48 h. The resulting yellow solution was placed in an iced bath to induce precipitation of the appropriate trans-platinum(II) complex which was recovered by filtration, washed intensively with water and diethyl ether, and air-dried at room temperature. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
55% | General procedure: The general synthetic procedure for the mixed transplatinum(II) complexes has been reported by Wilson and Lippard [4]. Cisplatin (100 mg, 0.333 mmol) was suspended in water (2 mL), and 8 equivalents of the appropriate alkylamine ligand were added. The resulting mixture was heated at 90 C until the solution became colourless. After the solution was cooled to room temperature, it was then treated with 37% (v/v) concentrated HCl (2.5 mL) followed by stirring and heating at 90 C for 48 h. The resulting yellow solution was placed in an iced bath to induce precipitation of the appropriate trans-platinum(II) complex which was recovered by filtration, washed intensively with water and diethyl ether, and air-dried at room temperature. |
Tags: 15663-27-1 synthesis path| 15663-27-1 SDS| 15663-27-1 COA| 15663-27-1 purity| 15663-27-1 application| 15663-27-1 NMR| 15663-27-1 COA| 15663-27-1 structure
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :